The 23andMe Research Institute bought the company's assets for $305 million, scotching a proposed sale to Regeneron ...
PALO ALTO, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- 23andMe Research Institute, a nonprofit medical research organization, ...
So, Regeneron's revenue rose 1.9% from $3.68 billion in Q2 2025 to $3.75 billion, beating consensus estimate by $160 million ...
On Wednesday, the U.S. Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals Inc.’s (NASDAQ: REGN) Eylea HD (aflibercept) Injection 8 mg for patients with macular edema following ...
Regeneron Pharmaceuticals received approval from the U.S. Food and Drug Administration for its eye treatment Eylea HD. The approval is for Eylea to treat macular edema following retinal vein occlusion ...
In a bid to deepen its manufacturing foothold in the U.S., Regeneron Pharmaceuticals in April pledged production and infrastructure investments surpassing $7 billion across North Carolina and its ...
SARATOGA SPRINGS, N.Y. — Gov. Kathy Hochul recently announced that Regeneron Pharmaceuticals, a global leader in biotechnology founded in New York State, will create 1,000 new jobs as part of a $2 ...
ALBANY, N.Y. (NEWS10) — A global biotechnology company with roots in the Capital Region is expanding into Saratoga County with a new facility. Regeneron Pharmaceuticals’ new property on Duplainville ...
The former Quad Graphics property is seen on Thursday in Saratoga Springs. Drug development and manufacturing firm Regeneron is building a 1-million-square-foot facility on the site. (Will ...
SARATOGA SPRINGS — Regeneron Pharmaceuticals, a global biotech company founded in New York City, is more than doubling its manufacturing capacity in the state, according to an announcement from the ...
On November 12, 2025, Regeneron filed a Motion to Strike Certain Affirmative Defenses and Dismiss Certain Counterclaims against Amgen in the aflibercept patent litigation in the U.S. District Court ...
Tarrytown-based Regeneron bought the former Avon complex at 1 Avon Place in Suffern in early 2024 for $38.875 million. The biotech company planned another $100 million in renovations at the site, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results